agilon health, inc.
Case Overview
59 Days Left to Seek Lead Plaintiff
| Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 03/02/2026 |
| Status: | Status: Investigating |
| Company Name: | Company Name: agilon health, inc. |
| Court: | Court: Eastern District of New York |
| Case Number: | Case Number: 1:25cv07167 |
| Class Period: | Class Period: 02/26/2025 - 08/04/2025 |
| Ticker: | Ticker: AGL |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired agilon health, inc. (“agilon” or the “Company”) (NYSE:AGL) securities during the period of February 26, 2025 through August 4, 2025, inclusive (“the Class Period”).
The lawsuit alleges that agilon made false and/or misleading statements and/or failed to disclose that: (1) agilon recklessly issued guidance for 2025 that the Company knew or should have known was not going to be achieved, given material industry headwinds of which the Company was aware; and (2) materially overstated the immediate positive financial impact from “strategic actions” taken by agilon to reduce risk.
On August 4, 2025, agilon issued a press release entitled “agilong Health Announces Leadership Transition” which stated that Defendant Steven Sell has “stepped down as President, CEO, and Director of the Board.” On the same day, in a current report filed on form 8-K with the SEC, the Company stated that “Mr. Sell’s departure was a termination without ‘cause’ under Mr. Sell’s employment agreement.”
On the same date, agilon also issued a press release entitled “agilon health Reports Second Quarter 2025 Results.” Commenting on the results, agilon’s Executive Chair stated that “as we progressed through this transition year, it’s become clear that the industry headwinds are more acute than previously expected.” Further, the release announced that the Company was “suspending its previously issued full-year 2025 financial guidance and related assumptions.” On this news, the price of agilon shares declined by $0.94 per share, or approximately 51.6%, from $1.82 per share on August 4, 2025 to close at $0.88 on August 5, 2025.
The lawsuit alleges that agilon made false and/or misleading statements and/or failed to disclose that: (1) agilon recklessly issued guidance for 2025 that the Company knew or should have known was not going to be achieved, given material industry headwinds of which the Company was aware; and (2) materially overstated the immediate positive financial impact from “strategic actions” taken by agilon to reduce risk.
On August 4, 2025, agilon issued a press release entitled “agilong Health Announces Leadership Transition” which stated that Defendant Steven Sell has “stepped down as President, CEO, and Director of the Board.” On the same day, in a current report filed on form 8-K with the SEC, the Company stated that “Mr. Sell’s departure was a termination without ‘cause’ under Mr. Sell’s employment agreement.”
On the same date, agilon also issued a press release entitled “agilon health Reports Second Quarter 2025 Results.” Commenting on the results, agilon’s Executive Chair stated that “as we progressed through this transition year, it’s become clear that the industry headwinds are more acute than previously expected.” Further, the release announced that the Company was “suspending its previously issued full-year 2025 financial guidance and related assumptions.” On this news, the price of agilon shares declined by $0.94 per share, or approximately 51.6%, from $1.82 per share on August 4, 2025 to close at $0.88 on August 5, 2025.